Evidence map›Paper›PMID 37029546›Full record

ArticleIntegrative cancer therapies

Extract of

Youyang Shi, Yuanyuan Wu, Man Shen, Jianfeng Yang, Yuenong Qin, Sheng Liu, Chenping Sun

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Integrative cancer therapies. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Antiviral and Immune Enhancement Effect ofMolecules (Basel, Switzerland) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Youyang ShiLongHua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.ORCID 0000-0001-8990-2550
Yuanyuan WuLongHua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Man ShenShanghai University of Traditional Chinese Medicine, Shanghai, China.
Jianfeng YangLongHua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Yuenong QinLongHua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Sheng LiuLongHua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Chenping SunLongHua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Shanghai University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Doxorubicin (Dox) is a first-line chemotherapeutic agent applied in cancer treatment. Its long-term anticancer efficacy is restricted mainly due to its subsequent cardiotoxicity for patients.

Indexed as

Antineoplastic AgentsHeart DiseasesNeoplasmsPlatycodonAnimalsApoptosisCardiotoxicityDoxorubicinMiceMyocytes, CardiacAntineoplastic AgentsDoxorubicinbreast cancercardiotoxicitydoxorubicinPlatycodon grandiflorum (PG)

Identifiers

PMID37029546
PMCPMC10087645
OpenAlexW4362716841

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.